Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled time : 17:00 save search
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | $399.92 1.43% 1.45% 1.1M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
vx-147 disease kidney treatment trial
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.1M
|
Health Technology
|
| O: 7.33%
H: 3.1%
C: -13.66%
first disease cell agreement therapy
Avidity Biosciences Honors Rare Disease Day®
Published: 2024-02-29 (Crawled : 17:00) - prnewswire.com
RNA | News M | $24.16 6.29% 5.96% 910K
|
Health Technology
|
| O: 19.99%
H: 6.28%
C: -0.05%
day rare disease
Global Respiratory Disease Vaccine Market Set for Growth, Fueled by Aging Populations and Vaccine Mandates - Trends, Opportunities, and Forecasts, 2018-2028F
Published: 2024-01-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: -0.15%
AZNCF | News | $138.73 1.86% -4.19% 3.6K
|
Health Technology
|
| O: 2.63%
H: 0.8%
C: 0.75%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
AZN | News | $70.13 2.31% 2.24% 4.3M
|
Health Technology
|
| O: 1.8%
H: 0.14%
C: -0.89%
disease vaccine respiratory global set market
Global Cystic Fibrosis Lung Disease Research Report 2023: Analysis and Forecasts by Drug Type, Route of Administration, Distribution Channel, Region, and Country 2019-2029
Published: 2024-01-09 (Crawled : 17:00) - prnewswire.com
NVSEF | News | $95.11 5.4% 6.88% 490
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: -0.46%
H: 0.74%
C: -0.19%
lung drug disease report distribution fibrosis research global
Asia-Pacific Emerging Infectious Disease Diagnostics Market Analysis and Forecast, 2023-2033 - Market Projected to Reach $10.83 Billion by 2033
Published: 2023-12-21 (Crawled : 17:00) - prnewswire.com
PKX | News | $71.6 1.43% -1.68% 150K
|
Non-Energy Minerals
|
| O: 0.97%
H: 0.12%
C: -0.15%
disease reach diagnostics market
Low-Density Lipoprotein Test Global Market Report 2023, By Product Type (LDL-C; LDL-P; LDL-B) , By Component, By Disease Type, By Distribution Channel and By End User
Published: 2023-12-11 (Crawled : 17:00) - prnewswire.com
QGEN | $41.22 3.05% -0.41% 1M
|
Health Technology
|
| O: -0.02%
H: 0.9%
C: 0.77%
NVS | News | $95.12 0.81% 5.43% 2.3M
|
Health Technology
|
| O: 0.75%
H: 0.55%
C: 0.27%
DHR | $236.08 0.24% -0.88% 2.2M
|
Health Technology
|
| O: 0.27%
H: 1.66%
C: 1.5%
ABT | News | $107.07 -0.2% -0.09% 3.8M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
QGEN | $41.22 3.05% -0.41% 1M
|
Health Technology
|
| O: -0.02%
H: 0.9%
C: 0.77%
disease report test distribution global market
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Published: 2023-12-08 (Crawled : 17:00) - globenewswire.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
first disease breast cancer treatment therapy show
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
Published: 2023-12-07 (Crawled : 17:00) - globenewswire.com
ZVSA | $0.5748 -1.91% -1.88% 240K
|
|
| O: -42.06%
H: 42.74%
C: -7.26%
disease kidney publication therapeutics diabetes diabetic
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group
Published: 2023-11-03 (Crawled : 17:00) - biospace.com/
NMLSF | $0.0088 -3.3% 400.0% 10K
|
n/a
| Email alert
Add to watchlist
rare disease group
Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients
Published: 2023-10-25 (Crawled : 17:00) - globenewswire.com
BIVI | $0.4832 -0.68% -0.58% 440K
|
Health Technology
|
| O: -4.48%
H: 14.06%
C: -1.56%
ne3107 disease active alzheimer’s impact imaging
Pancreatitis Disease Market Insights: Epidemiology Study, Drug Development, Clinical Trial and Price Reimbursement | Disease Landscape Insights
Published: 2023-10-12 (Crawled : 17:00) - prnewswire.com
IDXX | $479.57 0.68% 0.7% 420K
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -4.24%
BIIB | $194.11 -0.14% -0.15% 930K
|
Health Technology
|
| O: 0.15%
H: 0.41%
C: -2.22%
drug disease trial market
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Published: 2023-08-14 (Crawled : 17:00) - biospace.com/
QRON | $0.213 0% 3.2K
|
Manufacturing
| Email alert
Add to watchlist
patent disease application
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease
Published: 2023-08-09 (Crawled : 17:00) - biospace.com/
HOTH | $1.15 -3.81% 1.2% 15K
|
Health Technology
|
| O: 8.89%
H: 2.04%
C: 2.04%
disease positive treatment preclinical alzheimer's therapeutics ht-alz results
Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Published: 2023-07-17 (Crawled : 17:00) - globenewswire.com
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
fda disease rsv
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
Published: 2023-05-25 (Crawled : 17:00) - biospace.com/
ABBV | News | $167.89 0.89% 0.51% 3.6M
|
Health Technology
|
| O: -0.79%
H: 0.12%
C: -1.01%
rinvoq disease results
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
Published: 2023-05-24 (Crawled : 17:00) - biospace.com/
VCYT | News | $19.85 2.06% 2.02% 650K
|
Health Technology
|
| O: -1.42%
H: 1.83%
C: 1.21%
lung disease genomic cancer
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
Published: 2023-05-19 (Crawled : 17:00) - biospace.com/
NBIX | News M | $133.66 1.26% 1.12% 460K
|
Health Technology
|
| O: -0.6%
H: 0.9%
C: -0.25%
disease lancet publication treatment results study
Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board
Published: 2023-04-21 (Crawled : 17:00) - biospace.com/
KPRX | $0.485 -1.08% -1.07% 97K
|
Manufacturing
|
| O: 1.42%
H: 15.4%
C: 12.89%
disease
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
Published: 2023-04-05 (Crawled : 17:00) - biospace.com/
LLY | News | $731.33 0.69% 0.36% 1.7M
|
Health Technology
|
| O: 0.98%
H: 1.89%
C: 1.16%
ACIU | $2.42 2.54% 2.68% 210K
|
Health Technology
|
| O: -1.57%
H: 6.82%
C: 2.27%
disease alzheimer’s
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Your saved searches
Save your searches and get alerts when important news are released.